Literature DB >> 20143744

[A FRAX model for the assessment of fracture probability in Belgium].

A Neuprez1, H Johansson, J A Kanis, E V McCloskey, A Odén, O Bruyère, M Hiligsmann, J P Devogelaer, J M Kaufman, J Y Reginster.   

Abstract

The objective of this study was to evaluate a Belgian version of the WHO fracture risk assessment (FRAX) tool to compute 10-year probabilities of osteoporotic fracture in men and women. A particular aim was to determine fracture probabilities that corresponded to the reimbursement policy for the management of osteoporosis in Belgium and the clinical scenarios that gave equivalent fracture probabilities. Fracture probabilities were computed from published data on the fracture and death hazards in Belgium. Probabilities took account of age, sex, the presence of clinical risk factors and femoral neck BMD. Fracture probabilities were determined that were equivalent to intervention (reimbursement) thresholds currently used in Belgium. Fracture probability increased with age, lower BMI, decreasing BMD T-Score, and all clinical risk factors used alone or combined. The FRAX tool has been used to identify possible thresholds for therapeutic intervention in Belgium, based on equivalence of risk with current guidelines. The FRAX model supports a shift from the current DXA based intervention strategy, towards a strategy based on fracture probability of a major osteoporotic fracture that in turn may improve identification of patients at increased fracture risk. The approach will need to be supported by health economic analyses.

Entities:  

Mesh:

Year:  2009        PMID: 20143744

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN: 0370-629X


  17 in total

Review 1.  Development and use of FRAX in osteoporosis.

Authors:  J A Kanis; E V McCloskey; H Johansson; A Oden; O Ström; F Borgström
Journal:  Osteoporos Int       Date:  2010-05-13       Impact factor: 4.507

2.  Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK-an analysis of anonymous website activity.

Authors:  E V McCloskey; H Johansson; N C Harvey; J Compston; J A Kanis
Journal:  Osteoporos Int       Date:  2016-07-20       Impact factor: 4.507

3.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids.

Authors:  J A Kanis; H Johansson; A Oden; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-01-13       Impact factor: 4.507

4.  Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX) to assess the 10-year probability of fracture.

Authors:  O Bruyère; D Nicolet; S Compère; V Rabenda; P Jeholet; B Zegels; P Maassen; G Pire; J Y Reginster
Journal:  Rheumatol Int       Date:  2012-07-29       Impact factor: 2.631

5.  The distribution of FRAX(®)-based probabilities in women from Japan.

Authors:  John A Kanis; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  J Bone Miner Metab       Date:  2012-08-22       Impact factor: 2.626

Review 6.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

Review 7.  A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world.

Authors:  William D Leslie; John T Schousboe
Journal:  Curr Osteoporos Rep       Date:  2011-09       Impact factor: 5.096

8.  Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Authors:  O Ström; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2012-12-07       Impact factor: 4.507

9.  Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria.

Authors:  O Bruyère; M Fossi; B Zegels; L Leonori; M Hiligsmann; A Neuprez; J-Y Reginster
Journal:  Rheumatol Int       Date:  2012-07-28       Impact factor: 2.631

10.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Authors:  J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.